TW202535468A - 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 - Google Patents

使用免疫檢查點抑制劑抗體治療癌症之方法和組合

Info

Publication number
TW202535468A
TW202535468A TW114101922A TW114101922A TW202535468A TW 202535468 A TW202535468 A TW 202535468A TW 114101922 A TW114101922 A TW 114101922A TW 114101922 A TW114101922 A TW 114101922A TW 202535468 A TW202535468 A TW 202535468A
Authority
TW
Taiwan
Prior art keywords
antigen
antibody
binding fragment
ctla
dose
Prior art date
Application number
TW114101922A
Other languages
English (en)
Chinese (zh)
Inventor
約翰 庫爾蘭德
亞歷珍德拉 尼格羅
少群 張
Original Assignee
瑞典商阿斯特捷利康公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞典商阿斯特捷利康公司 filed Critical 瑞典商阿斯特捷利康公司
Publication of TW202535468A publication Critical patent/TW202535468A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW114101922A 2020-05-12 2021-05-12 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 TW202535468A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063023554P 2020-05-12 2020-05-12
US63/023,554 2020-05-12

Publications (1)

Publication Number Publication Date
TW202535468A true TW202535468A (zh) 2025-09-16

Family

ID=75977756

Family Applications (2)

Application Number Title Priority Date Filing Date
TW114101922A TW202535468A (zh) 2020-05-12 2021-05-12 使用免疫檢查點抑制劑抗體治療癌症之方法和組合
TW110117153A TWI870592B (zh) 2020-05-12 2021-05-12 使用免疫檢查點抑制劑抗體治療癌症之方法和組合

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW110117153A TWI870592B (zh) 2020-05-12 2021-05-12 使用免疫檢查點抑制劑抗體治療癌症之方法和組合

Country Status (12)

Country Link
US (3) US20220363762A1 (enExample)
EP (1) EP4021940A1 (enExample)
JP (2) JP7387912B2 (enExample)
KR (1) KR20230009354A (enExample)
CN (1) CN114729054A (enExample)
AU (3) AU2021269832B2 (enExample)
BR (1) BR112022021893A2 (enExample)
CA (1) CA3158607A1 (enExample)
IL (2) IL311936A (enExample)
MX (1) MX2022006728A (enExample)
TW (2) TW202535468A (enExample)
WO (1) WO2021228978A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024054897A1 (en) * 2022-09-07 2024-03-14 The University Of Chicago Methods for treating cancer with hyperactive adar enzymes
WO2025211692A1 (ko) * 2024-04-02 2025-10-09 (주)에트노바테라퓨틱스 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
AU2003221888B2 (en) 2002-04-11 2008-11-06 Medimmune, Llc Preservation of bioactive materials by spray drying
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
KR20100107083A (ko) 2002-12-17 2010-10-04 메디뮨 엘엘씨 생물활성 물질의 고압 분무 건조
NZ599405A (en) 2009-11-24 2014-09-26 Medimmune Ltd Targeted binding agents against b7-h1
MX389663B (es) * 2014-10-14 2025-03-20 Novartis Ag Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
HK1247578A1 (zh) * 2015-04-01 2018-09-28 Medimmune Limited 用於治疗非小细胞肺癌的组合抗pd-l1和抗ctla4抗体
US11214620B2 (en) * 2016-06-20 2022-01-04 F-Star Therapeutics Limited Binding molecules binding PD-L1 and LAG-3
CN109863402A (zh) * 2016-09-27 2019-06-07 鼎航医药股份有限公司 基于β2-糖蛋白1水平的用巴维昔单抗治疗癌症的方法和其测定
WO2018187227A1 (en) * 2017-04-03 2018-10-11 Concologie, Inc. Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
KR102693361B1 (ko) * 2017-05-26 2024-08-09 브루인 바이오사이언시스, 인크. 화학색전제
EP3630838A1 (en) 2017-06-01 2020-04-08 CytomX Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
WO2019241742A1 (en) * 2018-06-14 2019-12-19 Board Of Regents, The University Of Texas System Combination of ezh2 inhibitor and checkpoint therapy for the treatment of cancer
CA3102334A1 (en) * 2018-06-15 2019-12-19 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Also Published As

Publication number Publication date
JP2024016209A (ja) 2024-02-06
CA3158607A1 (en) 2021-11-18
AU2024202963A1 (en) 2024-05-30
BR112022021893A2 (pt) 2022-12-20
KR20230009354A (ko) 2023-01-17
EP4021940A1 (en) 2022-07-06
US20210355224A1 (en) 2021-11-18
AU2024266949A1 (en) 2024-12-19
CN114729054A (zh) 2022-07-08
AU2024202963B2 (en) 2025-11-20
WO2021228978A1 (en) 2021-11-18
JP7387912B2 (ja) 2023-11-28
JP2023524359A (ja) 2023-06-12
TWI870592B (zh) 2025-01-21
IL297640A (en) 2022-12-01
US20220363762A1 (en) 2022-11-17
TW202207976A (zh) 2022-03-01
MX2022006728A (es) 2022-06-09
US20240239893A1 (en) 2024-07-18
IL311936A (en) 2024-06-01
AU2021269832B2 (en) 2024-09-19
AU2021269832A1 (en) 2022-05-19

Similar Documents

Publication Publication Date Title
CN111065411A (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN114746117B (zh) 抗dll3药剂的给药方案
WO2020151759A1 (zh) 治疗肿瘤的联用药物组合物
US20240239893A1 (en) Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies
WO2020187152A1 (zh) 治疗小细胞肺癌的联用药物组合物
CN107614530A (zh) 用于多发性骨髓瘤（mm）的治疗
WO2020239085A1 (zh) 治疗黑色素瘤的联用药物组合物
JP2024519907A (ja) 尿路上皮癌の治療における、免疫チェックポイント阻害剤と併用での抗体薬物複合体の使用
WO2023174408A1 (zh) 抗tim-3抗体与抗pd-l1抗体的药物组合
US20240317854A1 (en) Methods for treating cancer with anti-ilt3 antibodies
EP4583880A1 (en) Compositions and methods for treating advanced solid tumors
US20240199758A1 (en) Method for allowing immune cells infiltration in tumors
EA050171B1 (ru) Способы и комбинации для лечения рака с применением антител, являющихся ингибиторами иммунных контрольных точек
WO2023230554A1 (en) Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2023174278A1 (zh) 抗tim-3抗体与去甲基化药物的药物组合
WO2025087358A1 (zh) 抗体药物偶联物用于治疗癌症的方法